Blogs

In the pharmaceutical and life sciences industries, ensuring Container Closure Integrity (CCI) is a critical requirement. The effectiveness of sterile packaging relies heavily on its ability to maintain a microbial barrier throughout its shelf life. This is where Container Closure Integrity Testing (CCIT) becomes essential. Regulatory bodies such as the FDA and USP have increasingly emphasized the need for deterministic and reliable methods of package integrity testing. Selecting the right CCIT method not only ensures regulatory compliance but also safeguards patient safety and product quality.

Among the most widely adopted CCIT methods today are Helium Leak Detection, MicroCurrent High Voltage Leak Detection (HVLD), and Vacuum Decay. Each technology offers unique capabilities suited to specific applications.

CCIT and Its Role in Ensuring Package Integrity

Container Closure Integrity Testing (CCIT) is the science of testing the ability of a container system (such as vials, syringes, or flexible packaging) to maintain a sterile barrier against potential contaminants. This includes assessing both physical and microbial barrier integrity. CCIT is integral to product stability, sterility assurance, and patient safety.

Deterministic CCIT methods, as opposed to probabilistic ones like dye ingress or bubble tests, provide quantifiable, reliable, and reproducible results. Deterministic methods are therefore preferred and recommended by USP <1207> guidelines.

CCI Testing Methods Offered by PTI

1. MicroCurrent HVLD Technology

High Voltage Leak Detection (HVLD) is a non-invasive, non-destructive method for testing the container closure integrity of liquid-filled parenteral products such as vials, syringes, ampoules, cartridges, and BFS containers. It works by applying an electrical micro-current across the container. If a leak exists, the electrical resistance drops, leading to increased current flow, signaling a breach.

PTI’s patented MicroCurrent HVLD technology advances this method by using about 50% less voltage and exposing the product to less than 5% of the energy used in conventional HVLD systems. This results in a safer, more efficient process that preserves both product quality and packaging integrity—especially beneficial for sensitive pharmaceutical and biologic products.

Benefits of MicroCurrent HVLD technology

• Non-destructive, non-invasive, no sample preparation
• Effective across all parenteral products, including extremely low conductivity liquids
• Lower voltage exposure produces no ozone, eliminating risk to the product and environment
• Listed in USP Chapter as recommended method for parenteral liquid package inspection
• Simplifies the inspection and validation process
• Scalable from the lab to production line

2. Vacuum Decay Technology

Vacuum Decay is a deterministic, quantitative, and non-destructive package integrity testing method ideal for a wide range of packaging formats. The test involves placing a sealed package in a custom vacuum chamber connected to an external vacuum source. Once the vacuum is applied, the system monitors for any rise in pressure within the chamber.

A defective package will allow air to escape, causing a detectable pressure change, while a leak-free package maintains the vacuum level. This method is highly reliable and adaptable for testing rigid, semi-rigid, and flexible packages made from both porous and non-porous materials, making it a trusted solution for quality control in production environments.

• Non-destructive test method that ensures quantitative test results
• ASTM test method F2338 and FDA Recognized Standard
• Referenced in USP 1207 guideline
• Cost-effective with rapid return on investment
• An All-around go-to technology for wide range of packaging formats

3. Helium Leak Detection Technology

Helium Leak Detection is an ultra-sensitive method for detecting micro-leaks in sealed containers using helium as a tracer gas. Due to its small molecular size and inert nature, helium can escape through the tiniest of defects without reacting with other substances. A Mass Spectrometer Leak Detector (MSLD) is used to measure the concentration of escaping helium and pinpoint the location of leaks.

This method is particularly valuable in early-stage R&D, component compatibility studies, and material selection processes. Helium testing is also ideal for products requiring deep cold storage, as it remains effective at ultra-low temperatures. Its sensitivity and precision make it a benchmark method for high-risk or high-value pharmaceutical packaging applications.

Applications of Helium Leak testing

• Ensuring Container Closure Integrity
• Selecting closure formulation and configuration
• Seal integrity monitoring during stability studies
• Extremely valuable in early-stage pharmaceutical product package system development

Each CCI technology serves a distinct purpose based on sensitivity requirements, packaging format, and product characteristics. In practice, many manufacturers use a combination of methods throughout the pharmaceutical product life cycle —leveraging helium leak detection for R & D studies, using MicroCurrent HVLD or vacuum decay for routine at-line testing. Selecting the right CCIT solution ensures package integrity, meets regulatory expectations, and ultimately protects patient safety.

In the high-stakes world of pharmaceutical manufacturing, ensuring the sterility and integrity of packaging is non-negotiable. Container Closure Integrity Testing (CCIT) is a fundamental quality assurance step that verifies whether packaging systems prevent microbial ingress and product leakage throughout a drug’s shelf life.

What is LOD in CCIT?

The Limit of Detection (LOD) in the context of CCIT refers to the smallest leak or defect size a test method can reliably identify with a high degree of confidence. It defines the detection threshold for the system and provides a benchmark for evaluating test performance. Unlike probabilistic methods such as dye ingress, deterministic methods—including Vacuum Decay, MicroCurrent High Voltage Leak Detection (HVLD), and Helium Leak Detection—offer more accurate, reproducible, and quantitative results, with well-defined LODs.

Why LOD is Important for Patient Safety and Regulatory Compliance

An undetected microleak in a sterile injectable can lead to contamination, reduced potency, or compromised efficacy—posing significant risks to patient health. Determining and validating the LOD ensures that the test method used can detect leaks that would compromise product integrity.

From a regulatory standpoint, standards such as USP <1207> and the upcoming USP <382> mandate the validation of CCIT methods, emphasizing the importance of deterministic testing and the Minimum Allowable Leakage Limit (MALL). Regulatory bodies increasingly expect manufacturers to validate their methods with detection capabilities down to defect sizes no larger than 20µm, with some deterministic technologies achieving reliable detection down to 5µm or smaller.

Deterministic CCI Test Methods Offered by PTI

Vacuum Decay Technology

Vacuum decay testing is a highly precise and reliable method for detecting leaks in packaging. It delivers consistent, quantitative results with clear pass/fail criteria. PTI’s VeriPac series was instrumental in establishing ASTM F2338, the standard for vacuum decay leak testing. Recognized in USP chapters on Container Closure Integrity (CCI), VeriPac systems use absolute or differential pressure transducers for non-destructive testing. This enables detection of micro-leaks and defects that may compromise package integrity, making it a trusted solution for CCI.

Helium Leak Detection

Helium Leak Detection (HLD) is a highly sensitive technique for identifying micro-leaks using helium as a tracer gas. Its inert, non-flammable nature and small atomic size allow for accurate leak rate measurements. Operating on mass spectrometry principles, HLD detects ionized helium to deliver precise, quantitative results. With detection sensitivity as low as 1×10?¹² l/s, it outperforms traditional methods like bubble or dye testing. Helium testing is ideal for evaluating packaging across various stages of the product life cycle, ensuring high integrity and performance.

MicroCurrent HVLD Technology

PTI’s MicroCurrent High Voltage Leak Detection (HVLD) is an advanced, non-destructive CCI testing method for liquid-filled parenteral containers. It supports applications like pre-filled syringes, vials, ampoules, BFS containers, and biologics. The system uses electrode probes to detect leaks by monitoring changes in current flow. Unlike traditional HVLD, it operates at ~50% lower voltage, reducing product exposure by over 95%. Its compatibility with low-conductivity solutions makes it ideal for sensitive biologics, ensuring compliance, safety, and product integrity.

Determining the Limit of Detection is not just a technical requirement—it’s a critical quality and compliance milestone in pharmaceutical manufacturing. With patient safety on the line and stringent regulatory standards in place, selecting and validating the appropriate CCIT method with an established LOD is essential. Technologies like Vacuum Decay and MicroCurrent HVLD provide a reliable pathway to compliant and high-performance leak testing, especially when validated with laser-drilled positive controls.

In the healthcare industry, packaging is not just a protective layer—it is a critical barrier that ensures sterility and safety until the point of use. Porous flexible pouches, commonly made from materials like Tyvek® or medical-grade paper, are widely used to package sterilized medical devices. Their ability to allow gas sterilants like ethylene oxide (EO) or steam to permeate while keeping contaminants out makes them indispensable. However, these same features make package integrity testing particularly challenging.

Porous Packaging: Trends and Challenges

With the increasing demand for sterile, ready-to-use medical devices, porous materials have become a staple in packaging. They support sterilization, are lightweight, and are often designed to meet sustainability goals. However, as package designs become more complex, the risks associated with undetected leaks or seal failures grow.

One of the major challenges is that porous materials do not behave the same way as non-porous films during integrity testing. Their ability to "breathe" makes it difficult for conventional methods like dye ingress or bubble emission to detect micro-leaks reliably. Moreover, visual inspection methods are subjective and may fail to identify defects that can lead to contamination. This calls for advanced testing systems that are both accurate and non-destructive.

Why Package Integrity Testing Matters?

In the context of medical device packaging, integrity testing is not optional—it’s a regulatory requirement and a patient safety imperative. Even a microscopic breach in the packaging can compromise sterility, which may lead to product recalls, regulatory penalties, or worse, patient harm.

Regulatory standards like ISO 11607 and guidance from the FDA emphasize the need for deterministic, validated testing methods over traditional, probabilistic techniques. The goal is to ensure that each package provides a robust sterile barrier throughout its shelf life.

Testing the Integrity of Flexible Porous Pouches with VeriPac Flex

VeriPac FLEX Systems offer a powerful, non-destructive solution for leak testing of pouches and other flexible packaging. Utilizing Vacuum Decay technology, these systems comply with ASTM F2338, a standard recognized by ISO 11607 and the FDA. They deliver exceptional sensitivity, capable of detecting defects as small as 10 to 20 microns, while providing accurate PASS/FAIL results along with quantitative leak rate data.

What makes VeriPac FLEX truly stand out is its unmatched versatility. Designed with multiple configurations, it easily adapts to a wide range of package formats and sizes—from small sachets to large bulk bags—without the need for changeovers. This flexibility significantly streamlines the testing process.

Unlike traditional destructive methods such as water bath or dye testing, Vacuum Decay eliminates subjectivity, reduces waste, and offers deeper insights into the overall packaging process. It also ensures a faster return on investment, making it a superior choice for container closure integrity testing (CCIT) in flexible packaging applications.

Benefits of VeriPac Flex

• Deterministic, quantitative test method
• Non-destructive, non-subjective, no sample preparation
• Test multiple packages in a single test cycle
• Cost effective with rapid return on investment
• Supports sustainable packaging and zero waste initiatives
• Simplifies the inspection and validation process
• Accurate and repeatable results
• ASTM test method and FDA standard
• USP < 1207> compliant

Testing the integrity of porous flexible pouches is one of the more complex tasks in medical device packaging. With the stakes so high, relying on outdated or inadequate methods is no longer an option. VeriPac Flex offers a modern, compliant, and efficient solution to this challenge. It brings together the precision of vacuum decay technology with the flexibility needed for diverse packaging formats, enabling manufacturers to meet both regulatory expectations and internal quality goals with confidence.

In the world of pharmaceutical packaging, where patient safety is non-negotiable, Container Closure Integrity Testing (CCIT) serves as a crucial safeguard. From sterile injectables to biologics and combination products, the integrity of a container-closure system can be the fine line between safety and risk. But as companies strive to optimize production efficiency, a recurring question emerges—how do we balance speed and sensitivity in package integrity testingpackage integrity testing, especially for high-risk applications?

Why Sensitivity Matters in High-Risk Applications

Imagine a life-saving biologic that loses sterility due to a microleak. The patient impact could be devastating. This is why sensitivity in CCIT isn't just a technical requirement—it’s a moral imperative.

High-risk products such as injectable biologics, ophthalmic solutions, or combination devices require maximum sensitivity to detect even the tiniest breaches in the container. These products are often sensitive to oxygen, moisture, or microbial ingress, and even a microscopic-defect can compromise their efficacy or safety. Traditional probabilistic methods like dye ingress or bubble emission simply lack the precision required for these applications. That's where deterministic technologies, especially High Voltage Leak Detection (HVLD), step in.

MicroCurrent High Voltage Leak Detection (HVLD) is a non-destructive method used in Container Closure Integrity Testing (CCIT), specifically designed to assess the integrity of parenteral packaging systems. This advanced testing technique is based on quantitative electrical conductivity measurements.

The principle of HVLDmc involves applying a low current signal across the package or container. In the presence of a leak, the electrical resistance of the package drops, leading to an increase in current—signaling a defect. MicroCurrent HVLD is particularly effective for liquid-filled, non-conductive containers and is applicable to a wide range of packaging formats, including:

• Pre-filled syringes
• Ampoules
• Drug product cartridges
• Liquid-filled vials
• Blow-Fill-Seal (BFS) containers

PTI’s MicroCurrent HVLD: Advancing Traditional HVLD Technology

PTI has redefined HVLD with the introduction of its MicroCurrent HVLD technology—a highly sensitive, non-invasive, and non-destructive CCIT method. This innovative approach extends the capabilities of conventional HVLD by using significantly lower voltages and currents, making it safer for delicate drug products and sensitive environments.

MicroCurrent HVLD is particularly suitable for testing liquid-filled containers, including challenging formulations such as low-conductivity sterile water for injection (WFI) and protein-rich drug suspensions.

PTI’s E-Scan HVLD system employs electrode probes to scan sealed, non-conductive containers. When a breach is present, the resulting variation in current flow identifies both the presence and approximate location of the defect. One of the key advantages of this technique is its ability to use approximately 50% less voltage, reducing product and environmental exposure to less than 5% of traditional HVLD voltage levels.

Moreover, the E-Scan HVLD system offers unmatched flexibility, seamlessly transitioning from offline laboratory testing to 100% inline automated inspection. It supports various packaging materials, including glass, plastic, and poly-laminate containers, making it an ideal solution for comprehensive parenteral package integrity testing.

Benefits of MicroCurrent HVLD:

• Deterministic, non-destructive, non-invasive
• High level of repeatability and accuracy
• Ideal package integrity solution for parenteral products
• Low voltage exposure to the product and environment
• Offline and 100% online inspection

In high-risk pharmaceutical applications, the choice between speed and sensitivity shouldn’t be a binary one. Instead, the goal should be to find a solution that optimizes both. Technologies like MicroCurrent HVLD offer a way forward—providing the precision required to detect critical defects, without sacrificing the throughput needed to meet production demands.